News
Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...
In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...
Asianet Newsable on MSN4h
Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman
Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced ...
The July CPI is expected to show a rise in annual retail inflation. AMC and Cisco among those reporting earnings. Nvidia ...
Pfizer ( PFE) shares gained on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings outlook, citing, among other ...
TipRanks on MSN12h
Sarepta price target raised to $14 from $12 at Citi
Citi raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company’s Q2 sales beat estimates ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback